Friday, September 11, 2026 — Week 37 CAMP4 — ASCEND EXPANDS TO THE UK - UK MHRA authorizes UK sites in CAMP4's Phase 1/2 CMP-002 trial. - UK joins Australia + Argentina. EU filing remains under review. - First-in-human trial still targeted to begin Q4 2026. - Another major step toward our first disease-modifying clinical trial. investors.camp4tx.com/news-releases/news-release-details/camp4-therapeutics-receives-authorization-united-kingdom-phase CAMP4 ANALYST DAY — SEPT. 28 - 12–1:30 PM ET. Trial design + unmet need + early pipeline. - CURE SYNGAP1 participating investors.camp4tx.com/news-events/events - We will have a day after, webinar, stay tuned for details. USA TODAY — SYNGAP1 IN PRINT - SYNGAP1 family story appeared in USA TODAY's national print edition this week. - Families need education, care + support TODAY. usatoday.com/story/life/health-wellness/2026/09/01/kids-special-education-school-shortage-care/90851980007 RARE-X + CITIZEN HEALTH - Glob...